Figure 2

Knockdown of MIR100HG confers growth disadvantage to AMKL cells. A) Number of shRNA- or ctrl-transduced Meg-01 cells (n = 2). B) Fraction of Cerulean⁺ shRNA-transduced cells at indicated time points of culture is shown in relation to the ctrl construct (n = 2; Two-way ANOVA was performed to compare the mean of each construct at each time point to ctrl). C) Number of colonies from methylcellulose-based CFU assays of shRNA-transduced Meg-01 cells (n = 2). D) Cumulative number of CFUs after one round of replating of sh-MIR100HG #2 in Meg-01 cells (n = 2). E) Percentage of shRNA-transduced Meg-01 cells in subG1 (BrdU⁻/7-AAD⁻), G1 (BrdU^low/7-AAD^low/high), S-phase (BrdU⁺/7-AAD^low/high) and G2/M fraction (BrdU^low/7-AAD^high) (n = 2). Asterisks are indicated for subG1 and S phases. F) Percentage of apoptotic/dead (Annexin V⁺) shRNA-transduced Meg-01 cells after 5 days of culture (n = 2). G) Representative density plots of viable, Cerulean⁺ Meg-01 cells for indicated surface markers as measured by flow cytometry after 5 days of culture (n = 4). (A-G) Data are presented as mean ± s.d. *P < 0.05; **P < 0.01.